Tiziana Life Sciences Ltd (FRA:0RP)

Market Cap	134.01M +67.0%
Revenue (ttm)	n/a
Net Income	-10.93M
EPS	-0.10
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	1.060
Previous Close	1.030
Day's Range	1.060 - 1.060
52-Week Range	0.965 - 2.140
Beta	n/a
RSI	45.52
Earnings Date	May 4, 2026

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for u...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 9
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0RP

Financial Performance

Financial numbers in USD